VeriStrat(®) has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib.

Br J Cancer · 2012 · PMC3505013 · PMID 23079575

Europe PMC DOI

hedged sentence

0.2100

closest p · 4.2× alpha

0.2100

boldest claim

The sentences

did not reach statistical significanceP =0.21not close (p > 0.1)

The ‘good’ group had longer median OS and PFS (12.5 months and 5.5 months, respectively) than the ‘poor’ group (5.6 months and 2.7 months, respectively), although separation between groups did not reach statistical significance for either comparison (log-rank P =0.21, HR=0.45, 95% CI: 0.13–1.57 for OS and log-rank P =0.093, HR=0.26, 95% CI: 0.06–1.25 for PFS).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.